Competing interests
LVE, Nordisk, NB, Diabetes
KIDNEY, APC, DIABETES
JVR, VC, RRA, EG, NB, LVE, MVM, and PV are employees or contractors of Imcyse S.A., Liège, Belgium, and may hold stock options. RDL’s institution received study funding and materials from Imcyse. RDL received an honorarium from DMRR and took part in advisory boards for Diamyd and Provention. MAA’s institution received study funding and materials from Imcyse. MAA received medical writing and APC support from Imcyse; received grants from EFSD, Wellcome Trust, Cardiff University, Wales Kidney Research Unit, and INNODIA; received honoraria from Sanofi Diabetes, Eli Lilly, Boehringer Ingelheim, Astra Zeneca, MSD, Novo Nordisk and Bayer; received meeting support from Sanofi Diabetes, Eli Lilly, Takeda, Abbott, Merck, Novo Nordisk, NAPP, Miltenyi Biotec and Servier. CD, BK, and CB’s institutions received study funding and materials from Imcyse. CD received consultancy honoraria, medical writing, and APC support from Imcyse. PA and KRO declare no competing interests.